Some seeds refuse to die. Date palm seeds recovered from Herod’s Palace near Jerusalem, roughly 2,000 years old, have been ...

Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor and HER2, and is characterized by aggressive progression, therapeutic resistance and limited targeted-treatment ...

Radiation therapy remains one of the most widely deployed weapons in oncology, yet its effectiveness is routinely undermined by a frustrating biological reality: many cancer cells are simply better at ...

IMNN-001 is not recombinant IL-12 cytokine injected into the bloodstream. Instead, it instructs the patient’s own cells to produce IL-12 locally, activating both innate and adaptive immunity and ...

9月15日，浙江大学研究团队在期刊《MedComm》上发表了研究论文，题为“Cooccurrence of Homologous Recombination Deficiency and Mismatch Repair Deficiency in ...

Thanks to the work of Fred Hutch/University of Washington clinical researchers, a big discovery may soon make a “big, big ...

A large real-world study published in Nature Medicine demonstrates that whole-genome sequencing can identify actionable biomarkers in nearly three-quarters of solid cancer patients within routine ...

Our core product, senaparib (IMP4297), has already been commercialized, following its approval as 1L maintenance therapy for ...

I have completed a master's degree in a science-related graduate school and work as a researcher at a manufacturer. At "Kenro," I research prospective universities not just by their names or deviation ...

Cancer treatment has become highly personalised in recent years. Advanced technologies used to treat different cancers have moved far beyond the standard, commo ...

IMUNON, Inc. announced that the (IDMC) overseeing its ongoing Phase 2 minimal residual disease (MRD) translational study of IMNN-001 has revi ...

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.